Home LiteratureArticle Details
PMID: 2306791 Published · ppublish English Journal Article

Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain.

Cancer chemotherapy and pharmacology ·Vol. 25 ·No. 5 ·1990-00-00 ·Pages 320-5

Greig NH, Daly EM, Sweeney DJ, Rapoport SI

Abstract

Equimolar doses of chlorambucil (10 mg/kg) and the lipophilic chlorambucil derivative, chlorambucil-tertiary butyl ester (13 mg/kg), were given i.v. to rats. Plasma and brain concentrations of chlorambucil and its active metabolites, 3,4-dehydrochlorambucil and phenylacetic mustard, as well as of chlorambucil-tertiary butyl ester were then determined by HPLC between 2 and 240 min after drug administration. Chlorambucil demonstrated a monophasic disappearance from plasma following its administration, with a half-life of 28 min. Significant amounts of phenylacetic mustard were detected after 15 min, and this agent maintained high levels of active compounds in plasma throughout the study. Only low concentrations of chlorambucil and phenylacetic mustard were detected in brain between 2 and 120 min. Following equimolar chlorambucil-tertiary butyl ester administration, it rapidly disappeared from plasma, with a half-life of approximately 2 min, and maintained low plateau concentrations between 15 and 120 min after treatment. It was not detected thereafter, although significant amounts of chlorambucil and phenylacetic mustard were detected throughout the study. Significant amounts of chlorambucil-tertiary butyl ester entered and remained within the brain, achieving a peak concentration at 15 min and disappearing thereafter with a half-life of 37 min. Low levels of chlorambucil and phenylacetic mustard were also detected. Calculated from the areas under the concentration vs time curves of total active compounds derived from chlorambucil and chlorambucil-tertiary butyl ester in brain and plasma, the brain:plasma concentration integral ratios were 0.018 and 0.68, respectively. Following equimolar doses of chlorambucil and chlorambucil-tertiary butyl ester, a 7-fold greater concentration integral was achieved by chlorambucil-tertiary butyl ester in brain at a 5-fold lower plasma concentration integral. Chlorambucil-tertiary butyl ester may be of value in the treatment of brain-sequestered tumors.

MeSH Terms
Alkylating Agents Animals Blood Proteins/metabolism Brain/drug effects,metabolism Chemical Phenomena Chemistry, Physical Chlorambucil/analogs & derivatives,pharmacokinetics Chromatography, High Pressure Liquid Half-Life Injections, Intravenous Male Protein Binding Rats Rats, Inbred Strains
Chemicals
Alkylating Agents Blood Proteins chlorambucil-tertiary butyl ester Chlorambucil
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Greig N H
Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892.
Daly E M
Sweeney D J
Rapoport S I
References (30)
30 references, click to expand
  1. Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration.
    Cancer Chemother Pharmacol. 1990;25(5):311-9 PMID: 2306790
  2. Therapeutic potential for blood-brain barrier modification in malignant brain tumor.
    Prog Exp Tumor Res. 1984;28:51-66 PMID: 6484205
  3. Epidemiologic study of primary intracranial neoplasms.
    Arch Neurol. 1981 Apr;38(4):217-9 PMID: 7213145
  4. Methotrexate analogues. 21. Divergent influence of alkyl chain length on the dihydrofolate reductase affinity and cytotoxicity of methotrexate monoesters.
    J Med Chem. 1984 May;27(5):605-9 PMID: 6585550
  5. Trends in cancer mortality: US white males and females, 1968-83.
    Lancet. 1988 Mar 19;1(8586):633-6 PMID: 2894559
  6. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
    N Engl J Med. 1980 Dec 4;303(23):1323-9 PMID: 7001230
  7. Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination.
    Biochem J. 1953 Jan;53(1):110-7 PMID: 13032041
  8. Comparative physico-chemical properties, biological effects, and disposition in mice of four nitrogen mustards.
    Cancer Chemother Pharmacol. 1980;5(1):1-9 PMID: 7460189
  9. Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration.
    J Pharmacol Exp Ther. 1988 May;245(2):574-80 PMID: 2835475
  10. Epidemiology of brain tumors: the national survey of intracranial neoplasms.
    Neurology. 1985 Feb;35(2):219-26 PMID: 3969210
  11. Phase II trial of prednimustine in glioblastoma multiforme.
    Cancer Treat Rep. 1984 May;68(5):795-7 PMID: 6327038
  12. Dialkyl esters of methotrexate and 3',5'-dichloromethotrexate: synthesis and interaction with aldehyde oxidase and dihydrofolate reductase.
    Drug Metab Dispos. 1973 May-Jun;1(3):580-9 PMID: 4149453
  13. Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and beta, beta-difluorochlorambucil (CB 7103) in mice.
    Cancer Chemother Pharmacol. 1986;17(1):21-9 PMID: 3698173
  14. Synthesis and antitumor activity of 4-[p-[bis(2-chloroethyl)amino]phenyl]butyrates.
    J Pharm Sci. 1980 Oct;69(10):1232-4 PMID: 7420301
  15. Pharmacology of the nitrosoureas: an overview.
    Cancer Treat Rep. 1976 Jun;60(6):703-7 PMID: 821608
  16. Treatment of brain tumors.
    Med Clin North Am. 1977 Sep;61(5):1045-51 PMID: 197350
  17. The pharmacokinetics of prednimustine and chlorambucil in the rat.
    Cancer Chemother Pharmacol. 1981;6(1):85-91 PMID: 7273268
  18. Primary intracranial neoplasms in the elderly.
    Clin Geriatr Med. 1987 Nov;3(4):765-79 PMID: 3315167
  19. Optimizing drug delivery to brain tumors.
    Cancer Treat Rev. 1987 Mar;14(1):1-28 PMID: 3297321
  20. Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.
    Cancer Res. 1986 Jan;46(1):224-8 PMID: 2415246
  21. Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat.
    Cancer Chemother Pharmacol. 1988;21(1):1-8 PMID: 3342460
  22. Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system.
    Cancer Res. 1987 Mar 15;47(6):1571-6 PMID: 3815357
  23. Relationship of cancer and aging.
    Clin Geriatr Med. 1987 Aug;3(3):419-32 PMID: 3308041
  24. Problems of delivery of drugs to the brain.
    Pharmacol Ther. 1982;19(3):337-86 PMID: 6765182
  25. Current status of chemotherapy of brain tumours.
    Prog Exp Tumor Res. 1985;29:152-66 PMID: 3906760
  26. Chemotherapy of brain metastases: current status.
    Cancer Treat Rev. 1984 Jun;11(2):157-86 PMID: 6388835
  27. Age effects on haloperidol pharmacokinetics in male, Fischer-344 rats.
    J Pharmacol Exp Ther. 1982 May;221(2):434-8 PMID: 7077539
  28. Delivery of human interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat.
    J Pharmacol Exp Ther. 1988 May;245(2):581-6 PMID: 3367308
  29. Management of central nervous system metastases.
    Semin Oncol. 1977 Mar;4(1):81-91 PMID: 841354
  30. Pharmacologic studies on the dibutyl and gamma-monobutyl esters of methotrexate in the rhesus monkey.
    Cancer Chemother Pharmacol. 1982 Dec;10(1):55-61 PMID: 7160046
Article Info
Journal
Cancer chemotherapy and pharmacology
Abbr.
Cancer Chemother Pharmacol
ISSN
0344-5704
Published
1990-00-00
Pages
320-5
Language
English
Region
Germany
NLM ID
7806519
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]